The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels

Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance

(2014) Ignacio F. San Francisco et al.   BJU INTERNATIONAL

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells

(2014) Seung-Yon Lee et al.   CANCER LETTERS

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

(2014) Kouji Izumi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014) Tomasz M. Beer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer

(2013) Robert Amato et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

(2013) Kouji Izumi et al.   EMBO Molecular Medicine

Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1–10.0 ng/ml at population screening

(2013) Yasuhide Kitagawa et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

(2013) T-H Lin et al.   Cell Death & Disease

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level

(2011) Barry B. McGuire et al.   BJU INTERNATIONAL

Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer

(2011) Martin Andreas Røder et al.   BJU INTERNATIONAL

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis

(2011) Kouji Izumi et al.   BJU INTERNATIONAL

Low pretreatment total testosterone (

(2010) Evanguelos Xylinas et al.   BJU INTERNATIONAL

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coactivator selective regulation of androgen receptor activity

(2009) Irina U. Agoulnik et al.   STEROIDS